Physician profile
Rene Badillo
NPI 1275256265
$2,426.67
in general payments reported to CMS, 2019-2025
15 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $362 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412 · Travel and Lodging: $14.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.42 |
| Travel and Lodging | $14.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $463.64 | 2024-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $311.42 | 2025 | Zepbound |
| Novo Nordisk INC | $234.02 | 2025 | Ozempic |
| Viiv Healthcare Company | $220.89 | 2024-2025 | Apretude |
| Scpharmaceuticals INC. | $149.66 | 2025 | |
| Alnylam Pharmaceuticals INC. | $137.91 | 2025 | Onpattro |
| Sanofi US Services INC. | $132.10 | 2025 | |
| Janssen Biotech, INC. | $130.82 | 2025 | Tremfya |
| Globus Medical, INC. | $130.29 | 2025 | Senza |
| Alkermes, INC. | $124.99 | 2025 | Vivitrol |
| Genzyme Corporation | $122.80 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.94 | 2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $112.34 | 2025 | Austedo Xr |
| Dexcom, INC. | $22.81 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $15.04 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Badillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.